Loading clinical trials...

ZX008 Expanded Access Protocol | Clinical Trials | Clareo Health

Approved For MarketingNCT03780127

ZX008 Expanded Access Protocol

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.

Lead sponsor: Zogenix, Inc.•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 3

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125 · Dravet Syndrome

RECRUITINGPhase 1/2

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492 · Dravet Syndrome

RECRUITINGPhase 3

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770 · Dravet Syndrome

RECRUITINGPhase 2

BMB-101 in Absence Epilepsy and DEE

NCT06401538 · Absence Epilepsy, Jeavons Syndrome, and more

RECRUITINGPhase 4

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

NCT06598449 · Dravet Syndrome (DS), Children Under 2 Years

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 24, 2023Terms

Trial snapshot

StatusAPPROVED_FOR_MARKETING

Phase—

Enrollment—

Start date—

Last updatedOct 24, 2023

Condition

Dravet Syndrome

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions